Schmidt Carsten, Allen Stephen, Kopyt Nelson, Pergola Pablo
Medical Clinic II, Department of Gastroenterology, Hepatology, Endocrinology, Diabetology and Infectious Diseases, Klinikum Fulda, Pacelliallee 4, 36043 Fulda, Germany.
Medical Faculty, Friedrich Schiller University, 07747 Jena, Germany.
J Clin Med. 2021 Sep 28;10(19):4448. doi: 10.3390/jcm10194448.
Iron deficiency is the most common cause of anemia globally and is frequently reported in patients with underlying inflammatory conditions, such as inflammatory bowel disease (IBD) and chronic kidney disease (CKD). Ferric maltol is a new oral iron replacement therapy designed to optimize iron absorption while reducing the gastrointestinal adverse events associated with unabsorbed free iron. Ferric maltol has been studied in clinical trials involving almost 750 adults and adolescents with iron-deficiency anemia associated with IBD, CKD, and other underlying conditions, and it has been widely used in clinical practice. It is approved for the treatment of adults with iron deficiency with or without anemia, independent of the underlying condition, and is commercially available in Europe and the United States. We review the published evidence for ferric maltol, which demonstrates consistent and clinically meaningful improvements in hemoglobin and measures of iron availability (ferritin and transferrin saturation) and shows that it is well-tolerated over long-term treatment for up to 64 weeks-an important consideration in patients with chronic underlying conditions such as IBD and CKD. We believe that ferric maltol is an effective, convenient, and well-tolerated treatment option for iron deficiency and iron-deficiency anemia, especially when long-term management of chronic iron deficiency is required. Writing support was provided by Shield Therapeutics (Gateshead, UK).
缺铁是全球贫血最常见的原因，在患有潜在炎症性疾病的患者中经常有报告，如炎症性肠病（IBD）和慢性肾脏病（CKD）。麦芽糖铁是一种新型口服铁剂替代疗法，旨在优化铁的吸收，同时减少与未吸收的游离铁相关的胃肠道不良事件。麦芽糖铁已在涉及近750名患有与IBD、CKD及其他潜在疾病相关的缺铁性贫血的成人和青少年的临床试验中进行了研究，并已在临床实践中广泛应用。它被批准用于治疗有或无贫血的缺铁成人，与潜在疾病无关，在欧洲和美国均可商业购得。我们回顾了已发表的关于麦芽糖铁的证据，这些证据表明血红蛋白及铁利用指标（铁蛋白和转铁蛋白饱和度）有持续且具有临床意义的改善，并且表明在长达64周的长期治疗中耐受性良好——这对于患有IBD和CKD等慢性潜在疾病的患者是一个重要考量因素。我们认为，麦芽糖铁是治疗缺铁和缺铁性贫血的一种有效、方便且耐受性良好的治疗选择，尤其是在需要对慢性缺铁进行长期管理时。写作支持由Shield Therapeutics（英国盖茨黑德）提供。
